Although the results from these early-stage clinical trials seemed promising for individuals with TNBC BRCA1/2 mutant disease, the stage III clinical trial OlympiAD showed no benefit of adding PARPi to the standard of care for advanced breast cancers (61). The gene discussed is BRCA1; the disease is breast carcinoma.